CanCURE 2.0
Principal Investigator
Jean-Pierre Routy, MD
Theme 3 Co-Leader
Theme 2 Participant
Éric A. Cohen, PhD
Co-Investigators
Bill Cameron, MD, FRCPC, FACP
Theme 3 Participant
Cecilia Costiniuk, MD
Theme 2 Participant
Lead on the McGill Autopsy Biobank Initiative
Elie Haddad, MD
Theme 2 & 3 Participant
Emilia Liana Falcone, MD
Theme 1 & 3 Participant
Ashok Kumar, PhD
Theme 1 & 3 Participant
Mohammad-Ali Jenabian DVM, PhD
Theme 1 & 2 Participant
Michel J Tremblay,
PhD
michel.j.tremblay@crchudequebec.ulaval.ca
Centre hospitalier universitaire (CHU) de Québec Research Centre
Theme 1& 2 Participant
Steering Committee
CanCURE 2.0's Steering Committee (SC) includes the Team's seven Principal Investigators, as well as two Principle Knowledge Users that oversee and provide the community perspective. The SC is responsible for the overall management of the program and for setting scientific and training priorities.
Keith Fowke,
PhD
Theme 1 Participant
Lead of Mentoring & Training Program
Mario A.
Ostrowski,MD
Theme 1 & 3 Participant
Lead on Autopsy Biospecimens & New Inhibitor Studies
mario.ostrowski@gmail.com
Nicolas Chomont, PhD
Theme 1 Co-Leader
Theme 2 & 3
Participant
Thomas T. Murooka, PhD
Theme 1 Co-Leader
Jerome Estaquier, PhD
Theme 2 Co-Leader
Theme 3 Participant
SC members include:
Éric Cohen, SC Co-Chair, CanCURE 2.0 Lead Investigator, Principal Investigator
Jonathan Angel, SC Co-Chair, Principal Investigator
Petronela Ancuta, Principal investigator
Jérôme Estaquier, Principal Investigator
Thomas Murooka, Principal Investigator
Nicolas Chomont, Principal investigator
Jean-Pierre Routy, Principal Investigator
Ron Rosenes, Principle Knowledge User
Shari Margolese, Principle Knowledge User
Scientific Advisory Board
CanCURE 2.0 is guided by a Scientific Advisory Board comprising four world-renowned basic and clinical scientists with a proven track record in the field of HIV Cure research.
Principle Knowledge Users
Community Advisory Board
.png)
Claudette Cardinal
Community Advisor
Team Coordination
Partners
Clinical Trial Network
The CIHR Canadian HIV Trials Network (CTN) is an innovative partnership of clinical investigators, physicians, nurses, people living with HIV, pharmaceutical manufacturers and others that facilitate HIV clinical trials of the highest scientific and ethical standards.
ViiV Healthcare
Born out of a partnership between GSK and Pfizer in 2009, with Shionogi joining in 2012, ViiV Healthcare is determined to help end the HIV epidemic. Their one focused goal unites 1100 employees located across over 20 countries, with their expertise in research, manufacturing, policy and more. Viiv's current portfolio of 14 HIV treatments is thier first step in fighting back against the disease. ViiV Healthcare is dedicated to widening access to ensure those who need their medicines can receive them. Collaborations with organisations such as IAS, CHAI and MPP enable their medicines to make the greatest possible impact in countries around the world.
Gilead
Gilead's focuses on advancing the care of patients through its research and development efforts directly impacts our relationships with physicians, patients and their caregivers, and our employees. They provide physicians with the resources to better care for their patients by rapidly and efficiently discovering and developing innovative therapeutics. They collaborate with patient advocates, design drugs to enhance treatment regimens and implement effective patient assistance programs to ensure our efforts help meet the needs of patients and their caregivers.
Merck
Merck's vision is to make a difference in the lives of people globally through their innovative medicines, vaccines, and animal health products. They are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV.
Theratechnologies
Biolegend
BioLegend is a leading developer of cutting-edge antibodies and reagents provided for biomedical research worldwide. Their objective is to accelerate research and discovery by offering the highest quality products at an outstanding value, along with superior customer service and technical support.
Affiliated Universities & research centers
